Foghorn Therapeutics (FHTX) announced that Ryan Maynard will join the company as Chief Financial Officer, CFO, on February 23, 2026. Maynard joins Foghorn with over 25 years of executive experience driving financial strategy, capital markets execution, and operational performance across public and private biopharmaceutical companies. Prior to joining Foghorn, Maynard was most recently at Cara Therapeutics
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FHTX: